Gewinn- und Verlustrechnung von QuidelOrtho Corporation

QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Seasoned medical technology finance executive brings more than two decades of leadership at global public companies SAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company"), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M.

QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.

On June 16, 2026, QuidelOrtho Corp (QDEL) shares fell 3.3%, bringing the current price to $14.13. The stock has experienced significant volatility, with a 52-we

Investors need to pay close attention to QDEL stock based on the movements in the options market lately.

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?

QDEL's Q1 results show how a milder respiratory season can pressure revenue, margins and cash flow despite stable testing market share.

SAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients. Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy.

On May 28, 2026, QuidelOrtho Corp (QDEL) shares rose 6.0% today, bringing the current price to $13.06. Over the past year, the stock has experienced significant

SAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) – a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation.